Wechat official account

 

Headquarters: Building F2, 88 Kechuang, 6th St., Beijing , China
Beijing Office : Suite 2105, Building T2, Dazu Square, Beijing , China
Shanghai Office: 595 North Caoxi Road  Building A Suite 6009 , Shanghai China
Boston Office: 99 Hayden Ave, Lexington, MA 02421, US

Tel: +86  010-56315466

Fax: +86  010-56315314

 

 

Copyright: JACOBIO PHARMACEUTICALS GROUP CO., LTD.   Beijing ICP B 17065868-1   

 

 

  2020

  We entered into a license and collaboration agreement with AbbVie in relation to, amongst others, the research, development and commercialization of certain SHP2 inhibitors including JAB-3068 and JAB-3312 in May.

  Our IND application for JAB-8263 for the treatment of solid tumors was approved by the FDA in July.

  We have filed an IND application with the NMPA for JAB-8263 for the treatment of solid tumors, MF and AML in August.

  We received orphan-drug designation from the FDA for JAB-3312 for the treatment of esophageal cancer in September.

  2019

  We established our R&D center in Massachusetts in January.

  We received orphan-drug designation from the FDA for JAB-3068 for the treatment of esophageal cancer in February.

  We obtained the IND approval from the FDA for JAB-3312 in July

  We initiated the Phase I clinical trial for JAB-3312 in the US in September.

  We obtained the IND approval from the NMPA for JAB-3312 in September.

  We initiated the Phase IIa stage of Phase I/IIa clinical trial for JAB-3068 in China in October.

  2018

  We obtained the IND approval from the FDA for JAB-3068 in January.

  We initiated the Phase I clinical trial for JAB-3068 in the US in April.

  We obtained the IND approval from the NMPA for JAB-3068 in May.

  We initiated the Phase I clinical trial for JAB-3068 in China in November.

  Jacobio US was incorporated in the US in December.

  2017

  We submitted the IND filing for our Core Product, JAB-3068, with the FDA in December.

  2015

  Beijing Jacobio, our principal operating subsidiary, was incorporated in July.